Table 1.
Biochemical, serological, and virological data
|
Index
|
Normal range
|
December 2017
|
March 2018
|
April 2019
|
June 2019
|
August 2019
|
October 2019
|
June 2020
|
July 2021
|
| ALT (U/L) | < 40 | 13 | 36 | 11 | 14 | 31 | 24 | 17 | 13 |
| AST (U/L) | < 35 | 26 | 23 | 17 | 18 | 25 | 18 | 14 | 14 |
| TBIL (μmol/L) | < 15 | 9.7 | 6.2 | 6.2 | 9.7 | 9.8 | 8.6 | 9 | 8.2 |
| PT (s) | 11-13 | 12.2 | 17.9 | 12.5 | |||||
| INR | 0.8-1.5 | 1.01 | 1.55 | 0.97 | 1.09 | 0.96 | 0.93 | 0.93 | 1.06 |
| FIB (g/L) | 1.8-3.5 | 3.4 | 4.37 | 2.72 | |||||
| APTT (s) | 25-31.3 | 24.6 | 30.8 | 22.9 | |||||
| TT (s) | 14-21 | 18.5 | 16.3 | 17.8 | |||||
| AFP (ng/mL) | ≤ 7 | 2.16 | 1.77 | 1.67 | 1.75 | 1.86 | 1.79 | 2 | 1.7 |
| HBsAg (IU/mL) | < 1 | 0.650 | 0.377 | 0.287 | 0.330 | 0.371 | 0.288 | 0.394 | 0.397 |
| Anti-HBs (mIU/mL) | < 10 | > 1000 | > 1000 | > 1000 | > 1000 | > 1000 | > 1000 | > 1000 | > 1000 |
| HBeAg (S/Co) | < 1.0 | 60.64 | 134.4 | 62.69 | 27.9 | 17.72 | 12.79 | 10.4 | 11.82 |
| Anti-HBe (S/Co) | > 1.0 | 1.3 | 1.39 | 1.1 | 0.994 | 1.01 | 1.06 | 1.09 | 1.03 |
| Anti-HBc (S/Co) | > 1.0 | 0.009 | 0.007 | 0.007 | 0.008 | 0.008 | 0.007 | 0.007 | 0.006 |
| HBV DNA (IU/mL) | 3.82 × 104 | 6.82 × 105 | 2.72 × 104 | ||||||
| HCV DNA (IU/mL) | < 50 | < 50 | < 50 | < 50 | < 50 | < 50 | < 50 | < 50 | < 50 |
| HIV antibody | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| HLA | HLA-A2 | HLA-A2 | HLA-A2 | ||||||
| Hepatic steatosis on B-ultrasound | - | Yes | - | Yes | Yes | - | - | Yes |
ALT: Alanine transaminase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; PT: Prothrombin time; INR: International normalized ratio; FIB: Fibrinogen; APTT: Activated partial thromboplastin time; TT: Thrombin time; AFP: Alpha fetoprotein; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B envelope antigen; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; HLA: Human leukocyte antigen.